• 60 Degrees Pharmaceuticals posted a net loss attributable to shareholders of $2.09 million for three months ended March 31, 2026, widening from year-ago period.
• Product revenues - net of Discounts and Rebates slipped 0.89% to $162,092, with discounts and rebates rising 6% to $96,857.
• Gross margin fell 8.08 percentage points to 47.12% as cost of revenues increased 16.98% to $85,715.
• General and administrative expenses climbed 9.68% to $1.89 million, driven by higher sales, advertising and promotion costs plus higher audit, legal and professional fees.
• Cash and cash equivalents rose to $3.34 million at March 31, 2026; company estimated funds to remain viable through mid-September 2026, raising substantial doubt about ability to continue as a going concern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001554855-26-001058), on May 15, 2026, and is solely responsible for the information contained therein.